Você procurou por: alkilinanciomis (Lituano - Inglês)

gydytojams jau yra gerai zinoma antrini navik atsiradimo po gydymo alkilinanciomis medziagomis rizika.
the risk of these secondary cancers occurring after therapy with alkylating agents is already well-known to doctors.

veiklioji temodal medziaga, temozolomidas, priklauso vaist nuo vzio grupei, sie vaistai vadinami alkilinanciomis medziagomis.
the active substance in temodal, temozolomide, belongs to a group of anticancer medicines called alkylating agents.

nors ankstesnis gydymas alkilinanciomis medziagomis pries gydym zevalin yra placiai paplitusi procedra, taciau tikrasis zevalin vaidmuo si navik atsiradimui po gydymo zevalin nra zinomas, kadangi radiacija taip pat gal sukelti siuos navikus.
however, as previous treatment with alkylating agents is widespread prior to zevalin treatment, one does not know the exact role of zevalin when these cancers occur after treatment with zevalin, since radiation may potentially also cause these cancers.

toks latentinis periodas yra labai trumpas net ir alkilinanciam vaistui.
this latency period is very short even for an alkylating agent.